title: Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis.
abstract: Naturally occurring regulatory T-cells (Treg) exhibit impaired function in patients with relapsing-remitting multiple sclerosis (RRMS) resulting from an age-inappropriate disproportion between prevalences of newly generated CD31-coexpressing naive Treg and long-lived memory Treg in the periphery. Recent evidence suggests that the immunomodulatory action of glatiramer acetate (GA) includes effects on Treg function and frequencies. We prospectively assessed suppressive activities and frequencies of Treg and Treg subsets in 15 patients with RRMS undergoing long-term therapy with GA. Treatment for up to six months reconstituted naive Treg and increased total Treg numbers with concomitant reversion of the Treg defect.
authors: Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Germany.
authors: Juergen
authors: J
authors: Haas
authors: Mirjam
authors: M
authors: Korporal
authors: Bettina
authors: B
authors: Balint
authors: Benedikt
authors: B
authors: Fritzsching
authors: Alexander
authors: A
authors: Schwarz
authors: Brigitte
authors: B
authors: Wildemann
mesh_terms: D000328:Adult; D000954:Antigens, Surface / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D015704:CD4 Antigens / Q000378:metabolism; D002452:Cell Count; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques; D051858:Forkhead Transcription Factors / Q000378:metabolism; D000068717:Glatiramer Acetate; D006801:Humans; D007156:Immunologic Memory / Q000502:physiology; D056747:Immunomodulation / Q000502:physiology; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011446:Prospective Studies; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects / Q000276:immunology
chemical_list: D000954:Antigens, Surface; D015415:Biomarkers; D015704:CD4 Antigens; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; C508017:IL2RA protein, human; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D010455:Peptides; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D000068717:Glatiramer Acetate